Community oncology leaders emphasized provider-first AI adoption, starting with clear use cases, defined guardrails, and ...
Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young ...
This week, a Capitol hearing spotlights Medicare fraud gaps, reports warn of equity setbacks, community oncology boosts ...
Cell and gene therapies have a huge curative potential but come with a large price tag that can result in access barriers. At ...
The 2025 CAQH Index found that more than $20 billion in cost savings could be achieved with more adoption of automatic and ...
Emory validated AI outbound calls to collect home BP readings and support technique, improving hypertension star performance ...
Linvoseltamab activates T cells by targeting BCMA on MM cells and CD3 on T cells, facilitating tumor destruction. The LINKER-MM1 trial demonstrated a 71% ORR, with 45% achieving stringent complete ...
Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology ...
Compared with placebo, semaglutide achieved larger reductions in heavy-drinking days (−41.1 vs −26.4 percentage points) and ...
Only Iowa, Montana, and Nebraska plan pre-2027 implementation with disenrollment; Arkansas anticipates a July soft launch ...
Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces ...
Marc P. Bonaca, MD, MPH, and Josephine Harrington, MD, discuss the clinical value of the uACR test and why it remains underutilized. Chronic kidney disease (CKD) affects an estimated 37 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results